{"doi":"10.2147/dddt.s162214","title":"Safety and efficacy of durvalumab (MEDI4736) in various solid tumors","abstract":null,"journal":"Drug Design, Development and Therapy","year":2018,"id":592129,"datarank":2.2760209029747744,"base_score":3.8501476017100584,"endowment":3.8501476017100584,"self_citation_contribution":0.5775221402565088,"citation_network_contribution":1.6984987627182655,"self_endowment_contribution":0.5775221402565088,"citer_contribution":1.6984987627182655,"corpus_percentile":null,"corpus_rank":null,"citation_count":46,"citer_count":46,"citers_with_citation_signal":41,"citers_with_endowment":41,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":591877,"name":"Kai Shen","orcid":"0000-0002-7772-8011","position":1,"is_corresponding":false},{"id":1024195,"name":"Chenjing Zhu","orcid":"0000-0001-8798-6367","position":2,"is_corresponding":false},{"id":1515171,"name":"Qingfang Li","orcid":null,"position":3,"is_corresponding":false},{"id":1515172,"name":"Yunuo Zhao","orcid":null,"position":4,"is_corresponding":false},{"id":1515173,"name":"Xuelei Ma","orcid":null,"position":5,"is_corresponding":false},{"id":262632,"name":"Hui Yang","orcid":"0000-0002-2865-5311","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Safety and efficacy of durvalumab (MEDI4736) in various solid tumors","abstract":"INTRODUCTION: The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors. METHODS: A systematic search of PubMed, Embase, and related articles was performed. Safety data were analyzed using Comprehensive Meta-Analysis software program version 2. Ultimately, 17 studies with 1,529 patients were included in our analysis. RESULTS: The major adverse events associated with durvalumab were pruritus and fatigue, while pruritus, increased alanine transaminase, and increased aspartate aminotransferase were common among patients treated with a combination of durvalumab and tremelimumab. Higher PD-L1 expression was associated with a superior objective response rate. CONCLUSION: Durvalumab is safe in patients with many solid cancers and, in combination with tremelimumab, it has a tolerable safety profile and is associated with improved prognosis. PD-L1 expression is a biomarker of the efficacy of durvalumab.","is_dataset_classified":null,"base_score":3.8501476017100584,"endowment":3.8501476017100584,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"30013326","pmcid":"PMC6038862","openalex_id":"https://openalex.org/W2855897811","authors":[],"funders":[],"total_grants":0,"fwci":1.9733,"citation_percentile":0.89960157,"influential_citations":0,"citation_trend":[{"year":2019,"count":5},{"year":2020,"count":8},{"year":2021,"count":11},{"year":2022,"count":10},{"year":2023,"count":5},{"year":2024,"count":4},{"year":2025,"count":2},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by-nc","oa_locations":[{"url":"https://www.dovepress.com/getfile.php?fileID=43004","host_type":"journal"},{"url":"https://www.dovepress.com/getfile.php?fileID=43004","host_type":"publisher"},{"url":"https://doi.org/10.2147/dddt.s162214","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/30013326","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6038862","host_type":"repository"},{"url":"https://doaj.org/article/75a1e0abd511419baed3a3b457d7a0fa","host_type":"repository"},{"url":"https://www.dovepress.com/safety-and-efficacy-of-durvalumab-medi4736-in-various-solid-tumors-peer-reviewed-article-DDDT","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC6038862","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC6038862?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","CAR-T cell therapy research","Colorectal and Anal Carcinomas","Antibodies, Monoclonal","Antineoplastic Agents, Immunological","Humans","Neoplasms","Software"],"mesh_terms":["Antineoplastic Agents, Immunological","Antibodies, Monoclonal","Humans","Neoplasms","Software"],"keywords":["Durvalumab","Tremelimumab","Medicine","Adverse effect","Oncology","Internal medicine","Immunotherapy","Cancer","Nivolumab","Adverse effects","Meta-analysis","efficacy","Solid Cancers"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Industry, innovation and infrastructure"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-26T12:20:07.573510Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}